Roman Urfer
Chief Executive Officer at Selonterra, Inc.
Profile
Roman Urfer is the founder and Chief Executive Officer of Selonterra, Inc. which is founded in 2015.
He is currently the Chief Development Officer at NeuroAssets Sàrl.
Dr. Urfer has previously worked as the Director & Chief Scientific Officer at M's Science Corp., Senior Vice President-Drug Discovery & Development at AGY Therapeutics, Inc., and as a Principal at Novartis Pharma AG.
He holds a doctorate from the University of Basel and an undergraduate degree from the Swiss Federal Institute of Technology.
Roman Urfer active positions
Companies | Position | Start |
---|---|---|
NeuroAssets Sàrl | Corporate Officer/Principal | - |
Selonterra, Inc.
Selonterra, Inc. BiotechnologyHealth Technology The American company focuses on developing therapies for neurodegenerative disorders such as Parkinson's and Alzheimer's disease. The company uses human genetics, molecular pathway analysis, and gene regulatory networks to identify disease-causing mechanisms and molecular targets to discover effective therapeutics. Selonterra's founders and advisors are experienced scientists and executives in the biotech and pharma industries, and they collaborate with other companies in their network. The company was founded by Anne Urfer-Buchwalder and Roman Urfer, with Roman Urfer serving as CEO since incorporation. | Chief Executive Officer | 30/11/2015 |
Former positions of Roman Urfer
Companies | Position | End |
---|---|---|
Novartis Pharma AG
Novartis Pharma AG Pharmaceuticals: MajorHealth Technology Novartis Pharma AG engages in the research in as well as the production and distribution of pharmaceutical, chemical, medical, and biotechnological products. It also provides related services. The company was founded on October 25, 1989 and is headquartered in Basel, Switzerland. | Corporate Officer/Principal | - |
AGY Therapeutics, Inc.
AGY Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology AGY Therapeutics, Inc. develops new therapies for diseases and disorders. It develops central nervous system therapeutics for the treatments of neurodegenerative diseases, CNS injuries, stroke, and schizophrenia. The company was founded by Robert Swanson and Karoly Nikolich in 1998 and is headquartered in South San Francisco, CA. | Corporate Officer/Principal | - |
M's Science Corp.
M's Science Corp. Miscellaneous Commercial ServicesCommercial Services M's Science Corp. engages in the research and development of drugs for the treatment of central nervous system (CNS) disorders and ocular diseases. It develops Cutamesine, an orally active compound that enhances neuroregeneration and facilitates the recovery of damaged CNS tissues from stress or ischemia-induced insults. The firm also develops therapeutic drugs for oncology. The company was founded by Shiro Mita in November 2000 and is headquartered in Kobe, Japan. | Chief Tech/Sci/R&D Officer | - |
Training of Roman Urfer
University of Basel | Doctorate Degree |
Swiss Federal Institute of Technology | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Private companies | 5 |
---|---|
AGY Therapeutics, Inc.
AGY Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology AGY Therapeutics, Inc. develops new therapies for diseases and disorders. It develops central nervous system therapeutics for the treatments of neurodegenerative diseases, CNS injuries, stroke, and schizophrenia. The company was founded by Robert Swanson and Karoly Nikolich in 1998 and is headquartered in South San Francisco, CA. | Health Technology |
Novartis Pharma AG
Novartis Pharma AG Pharmaceuticals: MajorHealth Technology Novartis Pharma AG engages in the research in as well as the production and distribution of pharmaceutical, chemical, medical, and biotechnological products. It also provides related services. The company was founded on October 25, 1989 and is headquartered in Basel, Switzerland. | Health Technology |
M's Science Corp.
M's Science Corp. Miscellaneous Commercial ServicesCommercial Services M's Science Corp. engages in the research and development of drugs for the treatment of central nervous system (CNS) disorders and ocular diseases. It develops Cutamesine, an orally active compound that enhances neuroregeneration and facilitates the recovery of damaged CNS tissues from stress or ischemia-induced insults. The firm also develops therapeutic drugs for oncology. The company was founded by Shiro Mita in November 2000 and is headquartered in Kobe, Japan. | Commercial Services |
NeuroAssets Sàrl | |
Selonterra, Inc.
Selonterra, Inc. BiotechnologyHealth Technology The American company focuses on developing therapies for neurodegenerative disorders such as Parkinson's and Alzheimer's disease. The company uses human genetics, molecular pathway analysis, and gene regulatory networks to identify disease-causing mechanisms and molecular targets to discover effective therapeutics. Selonterra's founders and advisors are experienced scientists and executives in the biotech and pharma industries, and they collaborate with other companies in their network. The company was founded by Anne Urfer-Buchwalder and Roman Urfer, with Roman Urfer serving as CEO since incorporation. | Health Technology |
- Stock Market
- Insiders
- Roman Urfer